mirus transit Search Results


98
Mirus Bio transit x2 dynamic delivery system
Transit X2 Dynamic Delivery System, supplied by Mirus Bio, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mirus+transit/TransIT-X2/pm42049736-204-25-29
Average 98 stars, based on 1 article reviews
transit x2 dynamic delivery system - by Bioz Stars, 2026-08
98/100 stars
  Buy from Supplier

97
Mirus Bio transit 293
Transit 293, supplied by Mirus Bio, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mirus+transit/TransIT+-293/pm41841741-370-23-24
Average 97 stars, based on 1 article reviews
transit 293 - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier

99
Mirus Bio transit lt1
Transit Lt1, supplied by Mirus Bio, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mirus+transit/TransIT+-LT1/10__1016_slash_j__neuron__2026__01__018-309-66-67
Average 99 stars, based on 1 article reviews
transit lt1 - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

97
Mirus Bio transit 2020
Transit 2020, supplied by Mirus Bio, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mirus+transit/TransIT+-2020/pm37803141-75-19-20
Average 97 stars, based on 1 article reviews
transit 2020 - by Bioz Stars, 2026-08
97/100 stars
  Buy from Supplier

96
Mirus Bio trans it lenti transfection reagent
Trans It Lenti Transfection Reagent, supplied by Mirus Bio, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mirus+transit/TransIT+-Lenti/pm41888396-55-17-20
Average 96 stars, based on 1 article reviews
trans it lenti transfection reagent - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

96
Mirus Bio mirus mrna transfection kit
A) Experimental workflow of GLORI-seq protocol to identify differential m 6 A following ZIKV infection (MOI 1, 48 hpi, n=3). B) Scatter plot showing ZIKV-induced changes in m 6 A levels of individual sites. Orange and blue dots represent upregulated (n=2004) and downregulated (n=502) m 6 A sites during ZIKV infection, respectively. C) Representative gene track plots of upregulated m 6 A in RIOK3 (upper panel), downregulated m 6 A in CIRBP (middle panel), and unchanged m 6 A in ACTB (lower panel). D) Metagene profiles showing the distributions of upregulated, downregulated, and unchanged m 6 A sites across the <t>mRNA</t> molecule. E) The top 6 motifs across upregulated, downregulated, and unchanged m 6 A sites and the proportion of m 6 A sites they contain. F) The absolute difference in m 6 A level of upregulated and downregulated m 6 A sites across the top 6 motifs. G) PANTHER GO enrichment analysis for genes with upregulated m 6 A sites using a binomial test with FDR correction (FDR p < 0.05).
Mirus Mrna Transfection Kit, supplied by Mirus Bio, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mirus+transit/TransIT+-mRNA/bio_rxiv__64898__2026__03__27__714597-165-15-15
Average 96 stars, based on 1 article reviews
mirus mrna transfection kit - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

96
Mirus Bio trans it insect reagent
A) Experimental workflow of GLORI-seq protocol to identify differential m 6 A following ZIKV infection (MOI 1, 48 hpi, n=3). B) Scatter plot showing ZIKV-induced changes in m 6 A levels of individual sites. Orange and blue dots represent upregulated (n=2004) and downregulated (n=502) m 6 A sites during ZIKV infection, respectively. C) Representative gene track plots of upregulated m 6 A in RIOK3 (upper panel), downregulated m 6 A in CIRBP (middle panel), and unchanged m 6 A in ACTB (lower panel). D) Metagene profiles showing the distributions of upregulated, downregulated, and unchanged m 6 A sites across the <t>mRNA</t> molecule. E) The top 6 motifs across upregulated, downregulated, and unchanged m 6 A sites and the proportion of m 6 A sites they contain. F) The absolute difference in m 6 A level of upregulated and downregulated m 6 A sites across the top 6 motifs. G) PANTHER GO enrichment analysis for genes with upregulated m 6 A sites using a binomial test with FDR correction (FDR p < 0.05).
Trans It Insect Reagent, supplied by Mirus Bio, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mirus+transit/TransIT+-Insect/pmc13094992-200-31-34
Average 96 stars, based on 1 article reviews
trans it insect reagent - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

96
Mirus Bio transit tko mir2150
A) Experimental workflow of GLORI-seq protocol to identify differential m 6 A following ZIKV infection (MOI 1, 48 hpi, n=3). B) Scatter plot showing ZIKV-induced changes in m 6 A levels of individual sites. Orange and blue dots represent upregulated (n=2004) and downregulated (n=502) m 6 A sites during ZIKV infection, respectively. C) Representative gene track plots of upregulated m 6 A in RIOK3 (upper panel), downregulated m 6 A in CIRBP (middle panel), and unchanged m 6 A in ACTB (lower panel). D) Metagene profiles showing the distributions of upregulated, downregulated, and unchanged m 6 A sites across the <t>mRNA</t> molecule. E) The top 6 motifs across upregulated, downregulated, and unchanged m 6 A sites and the proportion of m 6 A sites they contain. F) The absolute difference in m 6 A level of upregulated and downregulated m 6 A sites across the top 6 motifs. G) PANTHER GO enrichment analysis for genes with upregulated m 6 A sites using a binomial test with FDR correction (FDR p < 0.05).
Transit Tko Mir2150, supplied by Mirus Bio, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mirus+transit/TransIT-TKO/10__1016_slash_j__celbio__2026__100384-259-0-5
Average 96 stars, based on 1 article reviews
transit tko mir2150 - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

96
Mirus Bio transit pro system
A) Experimental workflow of GLORI-seq protocol to identify differential m 6 A following ZIKV infection (MOI 1, 48 hpi, n=3). B) Scatter plot showing ZIKV-induced changes in m 6 A levels of individual sites. Orange and blue dots represent upregulated (n=2004) and downregulated (n=502) m 6 A sites during ZIKV infection, respectively. C) Representative gene track plots of upregulated m 6 A in RIOK3 (upper panel), downregulated m 6 A in CIRBP (middle panel), and unchanged m 6 A in ACTB (lower panel). D) Metagene profiles showing the distributions of upregulated, downregulated, and unchanged m 6 A sites across the <t>mRNA</t> molecule. E) The top 6 motifs across upregulated, downregulated, and unchanged m 6 A sites and the proportion of m 6 A sites they contain. F) The absolute difference in m 6 A level of upregulated and downregulated m 6 A sites across the top 6 motifs. G) PANTHER GO enrichment analysis for genes with upregulated m 6 A sites using a binomial test with FDR correction (FDR p < 0.05).
Transit Pro System, supplied by Mirus Bio, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mirus+transit/TransIT+-PRO/pmc13048574-284-15-21
Average 96 stars, based on 1 article reviews
transit pro system - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

95
Mirus Bio rt icl e i n p re ss ctnnb1
A) Experimental workflow of GLORI-seq protocol to identify differential m 6 A following ZIKV infection (MOI 1, 48 hpi, n=3). B) Scatter plot showing ZIKV-induced changes in m 6 A levels of individual sites. Orange and blue dots represent upregulated (n=2004) and downregulated (n=502) m 6 A sites during ZIKV infection, respectively. C) Representative gene track plots of upregulated m 6 A in RIOK3 (upper panel), downregulated m 6 A in CIRBP (middle panel), and unchanged m 6 A in ACTB (lower panel). D) Metagene profiles showing the distributions of upregulated, downregulated, and unchanged m 6 A sites across the <t>mRNA</t> molecule. E) The top 6 motifs across upregulated, downregulated, and unchanged m 6 A sites and the proportion of m 6 A sites they contain. F) The absolute difference in m 6 A level of upregulated and downregulated m 6 A sites across the top 6 motifs. G) PANTHER GO enrichment analysis for genes with upregulated m 6 A sites using a binomial test with FDR correction (FDR p < 0.05).
Rt Icl E I N P Re Ss Ctnnb1, supplied by Mirus Bio, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mirus+transit/TransIT-siQUEST/pm42032684-63-8-21
Average 95 stars, based on 1 article reviews
rt icl e i n p re ss ctnnb1 - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

94
Mirus Bio transit ee hydrodynamic delivery solution
A) Experimental workflow of GLORI-seq protocol to identify differential m 6 A following ZIKV infection (MOI 1, 48 hpi, n=3). B) Scatter plot showing ZIKV-induced changes in m 6 A levels of individual sites. Orange and blue dots represent upregulated (n=2004) and downregulated (n=502) m 6 A sites during ZIKV infection, respectively. C) Representative gene track plots of upregulated m 6 A in RIOK3 (upper panel), downregulated m 6 A in CIRBP (middle panel), and unchanged m 6 A in ACTB (lower panel). D) Metagene profiles showing the distributions of upregulated, downregulated, and unchanged m 6 A sites across the <t>mRNA</t> molecule. E) The top 6 motifs across upregulated, downregulated, and unchanged m 6 A sites and the proportion of m 6 A sites they contain. F) The absolute difference in m 6 A level of upregulated and downregulated m 6 A sites across the top 6 motifs. G) PANTHER GO enrichment analysis for genes with upregulated m 6 A sites using a binomial test with FDR correction (FDR p < 0.05).
Transit Ee Hydrodynamic Delivery Solution, supplied by Mirus Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mirus+transit/TransIT+-EE/pm35697806-416-32-36
Average 94 stars, based on 1 article reviews
transit ee hydrodynamic delivery solution - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

94
Mirus Bio transit keratinocyte transfection reagent
(A) RT-qPCR of circE7 and E6*I normalized to linear E6 RNA from primary <t>keratinocytes</t> transfected with HPV16 WT or HPV16 mut2 genomes (circE7 splicing acceptor m 6 A motif mutation, no change to AA sequence). *p<0.05, ****p<0.0001. (B) Western blot of p53, GAPDH and HSP90 in whole cell extracts from Keratinocytes transfected with HPV16 WT or mut2 genomes. (C) Viral DNA detected by qPCR after HIRT DNA extraction out of primary Keratinocytes transfected with either wild type or mut2 HPV16. ****p<0.0001. (D) Crystal Violet staining of keratinocytes grown in 10% BCS DMEM for 2-6 weeks. Cells were transfected with either wild type HPV16 or HPV16 Mut2. Representative images (left) and quantification at week 6 (right). ***p<0.001
Transit Keratinocyte Transfection Reagent, supplied by Mirus Bio, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mirus+transit/TransIT+-Keratinocyte/bio_rxiv__64898__2026__03__09__710444-177-27-31
Average 94 stars, based on 1 article reviews
transit keratinocyte transfection reagent - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

Image Search Results


A) Experimental workflow of GLORI-seq protocol to identify differential m 6 A following ZIKV infection (MOI 1, 48 hpi, n=3). B) Scatter plot showing ZIKV-induced changes in m 6 A levels of individual sites. Orange and blue dots represent upregulated (n=2004) and downregulated (n=502) m 6 A sites during ZIKV infection, respectively. C) Representative gene track plots of upregulated m 6 A in RIOK3 (upper panel), downregulated m 6 A in CIRBP (middle panel), and unchanged m 6 A in ACTB (lower panel). D) Metagene profiles showing the distributions of upregulated, downregulated, and unchanged m 6 A sites across the mRNA molecule. E) The top 6 motifs across upregulated, downregulated, and unchanged m 6 A sites and the proportion of m 6 A sites they contain. F) The absolute difference in m 6 A level of upregulated and downregulated m 6 A sites across the top 6 motifs. G) PANTHER GO enrichment analysis for genes with upregulated m 6 A sites using a binomial test with FDR correction (FDR p < 0.05).

Journal: bioRxiv

Article Title: Alternative polyadenylation drives isoform-dependent m⁶A remodeling during Zika virus infection

doi: 10.64898/2026.03.27.714597

Figure Lengend Snippet: A) Experimental workflow of GLORI-seq protocol to identify differential m 6 A following ZIKV infection (MOI 1, 48 hpi, n=3). B) Scatter plot showing ZIKV-induced changes in m 6 A levels of individual sites. Orange and blue dots represent upregulated (n=2004) and downregulated (n=502) m 6 A sites during ZIKV infection, respectively. C) Representative gene track plots of upregulated m 6 A in RIOK3 (upper panel), downregulated m 6 A in CIRBP (middle panel), and unchanged m 6 A in ACTB (lower panel). D) Metagene profiles showing the distributions of upregulated, downregulated, and unchanged m 6 A sites across the mRNA molecule. E) The top 6 motifs across upregulated, downregulated, and unchanged m 6 A sites and the proportion of m 6 A sites they contain. F) The absolute difference in m 6 A level of upregulated and downregulated m 6 A sites across the top 6 motifs. G) PANTHER GO enrichment analysis for genes with upregulated m 6 A sites using a binomial test with FDR correction (FDR p < 0.05).

Article Snippet: 2.5 μg of HCV PAMP RNA was transfected into cells for 8 h using the Mirus mRNA transfection kit.

Techniques: Infection

A) and B) The correlation of m 6 A levels for sites detected by GLORI-seq between three biologically independent samples of mock- (A) or ZIKV-infected (B) Huh7 cells (48 hpi, MOI 1). C) Boxplots showing distribution of methylation level of m 6 A sites in Mock and ZIKV conditions. D) Principal component analysis of GLORI-seq m 6 A stoichiometry rates for Mock and ZIKV conditions. E) Metagene profiles showing the distributions of Mock and ZIKV m 6 A sites across the mRNA molecule. F) The top 6 motifs across Mock and ZIKV m 6 A sites and the proportion of m 6 A sites they contain.

Journal: bioRxiv

Article Title: Alternative polyadenylation drives isoform-dependent m⁶A remodeling during Zika virus infection

doi: 10.64898/2026.03.27.714597

Figure Lengend Snippet: A) and B) The correlation of m 6 A levels for sites detected by GLORI-seq between three biologically independent samples of mock- (A) or ZIKV-infected (B) Huh7 cells (48 hpi, MOI 1). C) Boxplots showing distribution of methylation level of m 6 A sites in Mock and ZIKV conditions. D) Principal component analysis of GLORI-seq m 6 A stoichiometry rates for Mock and ZIKV conditions. E) Metagene profiles showing the distributions of Mock and ZIKV m 6 A sites across the mRNA molecule. F) The top 6 motifs across Mock and ZIKV m 6 A sites and the proportion of m 6 A sites they contain.

Article Snippet: 2.5 μg of HCV PAMP RNA was transfected into cells for 8 h using the Mirus mRNA transfection kit.

Techniques: Infection, Methylation

A) and B) RT-qPCR analysis (relative to RPL30 ) of RNA expression of ALCAM-S and ALCAM-L (A) and NHSL1-S and NHSL1-L (B) upon DENV infection (48 hpi, MOI 1). C) and D) RT-qPCR analysis (relative to RPL30 ) of RNA expression of ALCAM-S and ALCAM-L (C) and NHSL1-S and NHSL1-L (D) upon WNV infection (48 hpi, MOI 0.01). E) and F) RT-qPCR analysis (relative to RPL30) of RNA expression of ALCAM-S and ALCAM-L (E) and NHSL1-S and NHSL1-L (F) upon HCV infection (48 hpi, MOI 1). G) and H) RT-qPCR analysis (relative to RPL30 ) of RNA expression of ALCAM-S and ALCAM-L (G) and NHSL1-S and NHSL1-L (H) upon transfection with HCV PAMP (8 hrs).

Journal: bioRxiv

Article Title: Alternative polyadenylation drives isoform-dependent m⁶A remodeling during Zika virus infection

doi: 10.64898/2026.03.27.714597

Figure Lengend Snippet: A) and B) RT-qPCR analysis (relative to RPL30 ) of RNA expression of ALCAM-S and ALCAM-L (A) and NHSL1-S and NHSL1-L (B) upon DENV infection (48 hpi, MOI 1). C) and D) RT-qPCR analysis (relative to RPL30 ) of RNA expression of ALCAM-S and ALCAM-L (C) and NHSL1-S and NHSL1-L (D) upon WNV infection (48 hpi, MOI 0.01). E) and F) RT-qPCR analysis (relative to RPL30) of RNA expression of ALCAM-S and ALCAM-L (E) and NHSL1-S and NHSL1-L (F) upon HCV infection (48 hpi, MOI 1). G) and H) RT-qPCR analysis (relative to RPL30 ) of RNA expression of ALCAM-S and ALCAM-L (G) and NHSL1-S and NHSL1-L (H) upon transfection with HCV PAMP (8 hrs).

Article Snippet: 2.5 μg of HCV PAMP RNA was transfected into cells for 8 h using the Mirus mRNA transfection kit.

Techniques: Quantitative RT-PCR, RNA Expression, Infection, Transfection

(A) RT-qPCR of circE7 and E6*I normalized to linear E6 RNA from primary keratinocytes transfected with HPV16 WT or HPV16 mut2 genomes (circE7 splicing acceptor m 6 A motif mutation, no change to AA sequence). *p<0.05, ****p<0.0001. (B) Western blot of p53, GAPDH and HSP90 in whole cell extracts from Keratinocytes transfected with HPV16 WT or mut2 genomes. (C) Viral DNA detected by qPCR after HIRT DNA extraction out of primary Keratinocytes transfected with either wild type or mut2 HPV16. ****p<0.0001. (D) Crystal Violet staining of keratinocytes grown in 10% BCS DMEM for 2-6 weeks. Cells were transfected with either wild type HPV16 or HPV16 Mut2. Representative images (left) and quantification at week 6 (right). ***p<0.001

Journal: bioRxiv

Article Title: Regulation and Function of the HPV16 CircE7 RNA

doi: 10.64898/2026.03.09.710444

Figure Lengend Snippet: (A) RT-qPCR of circE7 and E6*I normalized to linear E6 RNA from primary keratinocytes transfected with HPV16 WT or HPV16 mut2 genomes (circE7 splicing acceptor m 6 A motif mutation, no change to AA sequence). *p<0.05, ****p<0.0001. (B) Western blot of p53, GAPDH and HSP90 in whole cell extracts from Keratinocytes transfected with HPV16 WT or mut2 genomes. (C) Viral DNA detected by qPCR after HIRT DNA extraction out of primary Keratinocytes transfected with either wild type or mut2 HPV16. ****p<0.0001. (D) Crystal Violet staining of keratinocytes grown in 10% BCS DMEM for 2-6 weeks. Cells were transfected with either wild type HPV16 or HPV16 Mut2. Representative images (left) and quantification at week 6 (right). ***p<0.001

Article Snippet: Briefly, early passage primary keratinocytes were co-transfected with an equal DNA ratio of either pHPV16ANsL WT or Mut2 and pCAGGS-nlsCre plasmids (gift from CM Chiang lab) using TransIT Keratinocyte Transfection Reagent (MirusBio, MIR 2800) according to the manufacturer’s protocol.

Techniques: Quantitative RT-PCR, Transfection, Mutagenesis, Sequencing, Western Blot, DNA Extraction, Staining